{
    "id": 50626,
    "name": "gastrointestinal neuroendocrine tumor",
    "source": "DOID",
    "definition": "A gastrointestinal system cancer that has_material_basis_in neuroendocrine cells. [url:http\\://en.wikipedia.org/wiki/Neuroendocrine_tumor, url:http\\://www.cancer.gov/dictionary?CdrID=44904]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050626",
    "evidence": [
        {
            "id": 11996,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Votrient (pazopanib) treatment in patients with gastroenteropancreatic neuroendocrine tumors resulted in an overall response rate of 24% (19/124), stable disease in 39.5% (49/124), a progression free survival of 36% at six months, and a median overall survival of 10.2 months (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 446P).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9953,
                    "pubMedId": null,
                    "title": "Benefit of oral monotherapy with pazopanib in metastatic gastroenteropancreatic neuroendocrine tumours",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12909,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 28965,
                "profileName": "SSTR1 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12910,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 27894,
                "profileName": "SSTR2 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12911,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 28966,
                "profileName": "SSTR3 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12912,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 28967,
                "profileName": "SSTR4 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12914,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 28968,
                "profileName": "SSTR5 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02250885",
            "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315625",
            "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02955069",
            "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02963831",
            "title": "A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4978,
                    "therapyName": "Durvalumab + ONCOS-102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03043664",
            "title": "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6129,
                    "therapyName": "Lanreotide Depot + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03049189",
            "title": "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8572,
                    "therapyName": "177Lu-edotreotide",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03278379",
            "title": "Avelumab in G2-3 NET (NET-002)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03278405",
            "title": "Avelumab in G3 NEC (NET-001)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03411915",
            "title": "A Study of XmAb18087 in Subjects With NET and GIST",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7309,
                    "therapyName": "XmAb18087",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03420521",
            "title": "Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03670030",
            "title": "A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03879694",
            "title": "Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8087,
                    "therapyName": "Octreotide + Sargramostim + SurVaxM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03891784",
            "title": "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03901378",
            "title": "Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5145,
                    "therapyName": "Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04086485",
            "title": "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8723,
                    "therapyName": "lutetium Lu 177 dotatate + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04123262",
            "title": "Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        }
    ]
}